학술논문
식도암의 근치적 치료성적 및 예후인자
이용수 10
- 영문명
- Treatment Result and Prognostic Factors in Patients with Esophageal Cancer
- 발행기관
- 대한방사선종양학회
- 저자명
- 정원규(Weon Kuu Chung) 김수곤(Soo Kon Kim) 김민철(Min Chul Kim) 장명(Myoung Jang) 문성록(Sun Rock Moon)
- 간행물 정보
- 『대한방사선종양학회지』제13권 제3호, 233~241쪽, 전체 9쪽
- 주제분류
- 의약학 > 종양학
- 파일형태
- 발행일자
- 1995.09.30
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Purpose : To analyse clinical outcome and prognostic factors according to treatment modality, this paper report out experience of retrospective study of patients with esopahgeal cancer.
Materials and Methods : One hundred and ten patients with primary esopahgeal cancer who were treated in Presbyterian Medical Center from May 1985 to December 1992. We analysed these patients retrospectively with median follow up time of 28 months, one hundred and four patients(95%) were followed up from 15 to 69 months.
In methods, twenty-eight patients were treated with median radiation dose irradiated 54.3Gy only. Fifty-sex patients were treated with combined chemoradiothearpy. Sixteen cases of these patients were treated with concurrent chemoradiation and the other patients(forty cases) were treated sequential chemoradiotherapy. In concurrent chemoradiotherapy group, patients received 5-FU continuous Ⅳ infusion for 4 days. Cisplatin Ⅳ bolus, and concurrent esophageal irradiation to 30 Gy. After that patients received 5-FU continuous Ⅳ. Cisplatin bolus injection and Mitomycin-C bolus Ⅳ. Bleomycin continuous Ⅳ, and irradiation to 20 Gy. In sequential chemoradiotherapy group, the chmotherapy consisted of 5-FU 1,000mg/m² administred as a continuous 24 hour intravenous infusion during five days and Cisplatin 80-100mg/m² bolus injected, or Bleomycin. Vinblastine, Cisplatin, Methotrexate were used of 1 or 2 cycles. After preoperative concurrent chemoradiation, twenty-six patients underwent radical esopagectomy.
Results : Ninety-three patients could be examined for response assessment. By treatment modality, response rates were 85.1% for radiation alone group and 86.3% for combined chemoradaition group. But in operation group, after one cycle of concurrent chemoradiation treatment, response rate was 61.9%.
The pathologic complete response were 15.4% in peration group. Overall median survival was 11 months and actuarial 5-year survival rate was 8%. The median survival interval was 6 months for radiation alone group. 11 months for combined chemoradiation group and 19 months for operation group. And also median survival was 19 months for complete responder group that 8 months for noncomplete responder group. In univariative analysis, statistically significant prognostic factors were tumor size, clinical stage, tumor response, and operation. In multivariative analysis, significantly better survival was associated with clinical stage, tumor response, radiation dose, and operation.
Conclusion : Compared with radiotherapy alone, combined multimodality may imporve the median survival in patients with localized carcinoma of the esopahgus and toxicity is acceptable.
목차
해당간행물 수록 논문
- 소아암의 방사선 치료후 발생한 이차 악성 고형 종양
- 식도암의 근치적 치료성적 및 예후인자
- Malignant Fibrous Histiocytoma of the Maxilla
- 6 MeV 전자선의 측정과 모의계산에 대한 연구
- Gingko Biloba Extract가 C3H 마우스 섬유육종의 저산소세포 분획에 미치는 영향
- 국소적으로 진행된 직장암에 대한 근치적 수술 단독 치료군과 수술후 보조적 방사선 및 항암화학요법 병행군의 치료결과 분석
- 조직 불균질성에 의한 고에너지 광자선의 선량변화
- 비인두암의 방사선치료 결과
- Wedge Factor의 임상적 응용
- Intraluminal High-Dose-Rate Brachytherapy for the Tumors of Gastrointestinal Tract
- 병기 Ⅲ 자궁경부암의 방사선치료 결과
참고문헌
관련논문
의약학 > 종양학분야 BEST
- 방사선 치료에 내성이 유도된 두경부 편평세포암에 대한 종양살상 헤르페스 바이러스의 유전자 치료 효과
- 식도암에서 근치적 절제술 후 방사선치료의 역할
- 두경부암에서 면역회피 기전과 면역항암제 치료
의약학 > 종양학분야 NEW
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck
- Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!